Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAD52 | P43351 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932525 | 0.81 | HRH4 (0.45) | HRH3KDM4ECYP1A2ALDH1A1 | |
| SCHEMBL27471254 | 0.81 | GAA (0.46) | HRH3GAAKDM4ECYP2C9CYP2C19 | |
| SCHEMBL8185009 | 0.81 | POLB (0.36) | MAPTPOLBALDH1A1 | |
| SCHEMBL1772389 | 0.80 | CASP1 (0.43) | — | |
| SCHEMBL3219141 | 0.78 | NPC1 (0.55) | KDM4ESMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL743397 | 0.78 | MAPT (0.40) | SMN1; SMN2MAPTRAB9ANPC1CYP1A2 | |
| SCHEMBL2067822 | 0.78 | MAPT (0.36) | KDM4ESMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL1316269 | 0.77 | MAPT (0.41) | SMN1; SMN2MAPTRAB9ANPC1CYP1A2 | |
| SCHEMBL1773335 | 0.77 | HRH3 (0.45) | HRH3KDM4EMAPTALDH1A1 | |
| SCHEMBL8194170 | 0.76 | MAPT (0.48) | GAAKDM4ESMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065969-A1 | THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | claimed |
| US-10155767-B2 | Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-12-18 | — | — | US | disclosed |
| US-20180065969-A1 | THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155767-B2 | Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives | GAK, DCK, NRAS | HRH3 2150/4885GAA 4009/4885KDM4E 2270/4885 |
| US-20180065969-A1 | THERAPEUTIC AGENT OF ACUTE MYELOID LEUKEMIA CONTAINING 1,3,7-TRISUBSTITUTED 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDINE-2(1H)-ONE DERIVATIVES | GAK, DCK, NRAS | HRH3 2150/4885GAA 4009/4885KDM4E 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.